Pfizer / Merck bavencio research on maintenance treatment of refractory gastric cancer failed!

Immunotumor drugs have little effect on the treatment of gastric cancer Recently, Pfizer and Merck's bavencio failed to succeed in the trials of refractory gastric cancer Bavencio failed to beat two other treatment options after a successful round of chemotherapy in patients with advanced or inoperable gastric cancer in a phase 3 maintenance treatment study (javelin gastric 100), compared with continuing chemotherapy or the best supportive treatment for prolonging patients' lives, the two companies said recently The study found that bavencio did not show a good treatment advantage even in PD-1 / L1 positive patients who had historically shown better efficacy of PD-1 / L1 inhibitors Markusm, the coordinator of the trial? In a statement, hler said that advanced gastric cancer "rarely has immunogenicity, so far, there is no immunosuppressive checkpoint inhibitor that is superior to the treatment standard of chemotherapy." Researchers are now delving into the results to get useful information In fact, this is not the first time bavencio has failed in the study of gastric cancer In 2017, the researchers acknowledged that the drug did not significantly improve overall survival in patients with advanced gastric cancer compared to the best treatment available In addition, even market leading PD-1 drugs such as keytruda have not made a great breakthrough in the treatment of gastric cancer At the end of 2017, keytruda failed to prevent tumor progression or showed a significant survival advantage in patients with previously treated PD-L1 positive, advanced gastric cancer (keynote-061) In April 2019, the keynote-062 trial failed again Compared with chemotherapy alone, there was no significant difference in the total survival and progression free survival of keytruda combined chemotherapy patients, which did not reach the clinical end point However, keytruda, as a three-line treatment scheme in the keynote-059 study, showed some clinical benefits for patients with PD-L1 positive gastric cancer, which also made the drug obtain the accelerated approval of FDA in 2017 Another tumor blockbuster, opdivo, as a third-line treatment drug, has successfully improved the survival rate of patients with gastric cancer in Asia In the ono-4538-12 trial, the drug reduced the risk of death in patients with gastric cancer by 37%, extending life by an average of 5.32 months, compared with 4.14 months in the placebo group Although there seems to be no breakthrough in gastric cancer, bavencio has been recognized by the US FDA in terms of renal cancer The FDA has previously approved bavencio in combination with Pfizer's targeted anticancer drug inlyta for the first-line treatment of patients with advanced renal cell carcinoma However, the future prospect of the drug is not very optimistic The drug combination will compete with keytruda + inlyta and opdivo + yevoy In addition to being frustrated with gastric cancer, bavencio also faced three setbacks in the ovarian cancer trial, the most recent of which was used in combination with Pfizer's PARP drug, talzenna, for patients with previously untreated stage III or stage IV ovarian cancer